Literature DB >> 20730035

Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90.

Robert C Vasko1, Rodrigo A Rodriguez, Christian N Cunningham, Veronica C Ardi, David A Agard, Shelli R McAlpine.   

Abstract

Herein we show that San A-amide, a structurally unique molecule, influences a subset of cancer-related pathways involving Hsp90. We show that San A-amide specifically binds to the N-middle domain of Hsp90 allosterically disrupts the binding of proteins thought to interact with the Hsp90 C-terminal domain, while having no effect on an N-terminal domain client protein. This unique mechanism suggests that San A-amide is a potential tool for studying C-terminal binding proteins of Hsp90 as well as a promising lead in the development of new cancer therapeutics.

Entities:  

Year:  2010        PMID: 20730035      PMCID: PMC2922868          DOI: 10.1021/ml900003t

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  36 in total

1.  Role of the myosin assembly protein UNC-45 as a molecular chaperone for myosin.

Authors:  Jose M Barral; Alex H Hutagalung; Achim Brinker; F Ulrich Hartl; Henry F Epstein
Journal:  Science       Date:  2002-01-25       Impact factor: 47.728

Review 2.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death.

Authors:  C Jolly; R I Morimoto
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

3.  Evidence that the 90-kilodalton heat shock protein is associated with tubulin-containing complexes in L cell cytosol and in intact PtK cells.

Authors:  E R Sanchez; T Redmond; L C Scherrer; E H Bresnick; M J Welsh; W B Pratt
Journal:  Mol Endocrinol       Date:  1988-08

4.  Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells.

Authors:  Yuo-Sheng Chang; Lee-Chen Lee; Fang-Chun Sun; Chih-Chung Chao; Hua-Wen Fu; Yiu-Kay Lai
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

5.  Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.

Authors:  Megumi Senju; Naoko Sueoka; Akemi Sato; Kentaro Iwanaga; Yukinori Sakao; Shinji Tomimitsu; Masaki Tominaga; Koji Irie; Shinichiro Hayashi; Eisaburo Sueoka
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-09       Impact factor: 4.553

6.  Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A.

Authors:  Y Hwang; D Rowley; D Rhodes; J Gertsch; W Fenical; F Bushman
Journal:  Mol Pharmacol       Date:  1999-06       Impact factor: 4.436

7.  Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.

Authors:  Ami Citri; Judith Gan; Yaron Mosesson; Gyorgi Vereb; Janos Szollosi; Yosef Yarden
Journal:  EMBO Rep       Date:  2004-12       Impact factor: 8.807

8.  The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

Authors:  Daniela Matei; Minati Satpathy; Liyun Cao; Yi-Chun Lai; Harikrishna Nakshatri; David B Donner
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

9.  Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

Authors:  David B Solit; Iman Osman; David Polsky; Katherine S Panageas; Adil Daud; James S Goydos; Jerrold Teitcher; Jedd D Wolchok; F Joseph Germino; Susan E Krown; Daniel Coit; Neal Rosen; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines.

Authors:  Katerina Otrubova; Gerald Lushington; David Vander Velde; Kathleen L McGuire; Shelli R McAlpine
Journal:  J Med Chem       Date:  2008-01-11       Impact factor: 7.446

View more
  34 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  The conserved arginine 380 of Hsp90 is not a catalytic residue, but stabilizes the closed conformation required for ATP hydrolysis.

Authors:  Christian N Cunningham; Daniel R Southworth; Kristin A Krukenberg; David A Agard
Journal:  Protein Sci       Date:  2012-08       Impact factor: 6.725

4.  Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.

Authors:  Robert P Sellers; Leslie D Alexander; Victoria A Johnson; Chun-Chieh Lin; Jeremiah Savage; Ricardo Corral; Jason Moss; Tim S Slugocki; Erinprit K Singh; Melinda R Davis; Suchitra Ravula; Jamie E Spicer; Jenna L Oelrich; Andrea Thornquist; Chung-Mao Pan; Shelli R McAlpine
Journal:  Bioorg Med Chem       Date:  2010-07-22       Impact factor: 3.641

5.  Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.

Authors:  Veronica C Ardi; Leslie D Alexander; Victoria A Johnson; Shelli R McAlpine
Journal:  ACS Chem Biol       Date:  2011-10-17       Impact factor: 5.100

6.  Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds.

Authors:  Melinda R Davis; Erinprit K Singh; Hendra Wahyudi; Leslie D Alexander; Joseph B Kunicki; Lidia A Nazarova; Kelly A Fairweather; Andrew M Giltrap; Katrina A Jolliffe; Shelli R McAlpine
Journal:  Tetrahedron       Date:  2012-01-28       Impact factor: 2.457

Review 7.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

8.  Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.

Authors:  Jason Gavenonis; Nicholas E Jonas; Joshua A Kritzer
Journal:  Bioorg Med Chem       Date:  2014-06-14       Impact factor: 3.641

Review 9.  Inhibitors and chemical probes for molecular chaperone networks.

Authors:  Jason E Gestwicki; Hao Shao
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 10.  Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.

Authors:  Laura J Blair; Jonathan J Sabbagh; Chad A Dickey
Journal:  Expert Opin Ther Targets       Date:  2014-07-29       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.